USA - engelska - NLM (National Library of Medicine)

grifols usa, llc - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 500 [iu] in 10 ml - alphanine sd is indicated for the prevention and control of bleeding in patients with factor ix deficiency due to hemophilia b. alphanine sd contains low, non-therapeutic levels of factors ii, vii, and x, and, therefore, is not indicated for the treatment of factor ii, vii or x deficiencies. this product is also not indicated for the reversal of coumarin anticoagulant-induced hemorrhage, nor in the treatment of hemophilia a patients with inhibitors to factor viii. none known.

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antihemophilic factor viii (human) - injection, powder, for solution - 1000 iu/vial - antihemophilic factor viii (human) 1000 iu/vial

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antihemophilic factor viii (human) - injection, powder, for solution - 250 iu/vial - antihemophilic factor viii (human) 250 iu/vial

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antihemophilic factor viii (human) - injection, powder, for solution - 500 iu/vial - antihemophilic factor viii (human) 500 iu/vial

Australien - engelska - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - alpha-1-proteinase inhibitor, quantity: 1000 mg - diluent, not applicable - excipient ingredients: - prolastin-c is an alpha-1-proteinase inhibitor (human, alpha1-pi) indicated to increase serum alpha1-pi levels in adults with congenital deficiency of alpha-1 antitrypsin and with clinically significant emphysema (fev1 less than 80%). the data for clinical efficacy of prolastin-c is derived from changes in the biomarkers alpha-1 anti-protease level and ct lung density. efficacy on fev1 or patient relevant endpoints such as quality of life or pulmonary exacerbations has not been established in randomised clinical trials. clinical trials have only included patients who were not smoking.

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 1000 i.u. per 20ml - human antithrombin 1000 i.u. per 20ml

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human antithrombin - injection, powder, lyophilized, for solution - 500 i.u. per 10ml - human antithrombin 500 i.u. per 10ml

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antitetanus immunoglobulin (human) - injection - 250 iu/ml - antitetanus immunoglobulin (human) 250 iu/ml

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antihepatitis b immunoglobulin (human) - injection - 200 iu/ml - antihepatitis b immunoglobulin (human) 200 iu/ml

Singapore - engelska - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - human normal immunoglobulin - infusion, solution - 100mg/ml - human normal immunoglobulin 100mg/ml